Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib in Advanced Sarcomas with CDK4 Overexpression
NCT03242382Phase 2Recruiting
- Sponsor
- Spanish Group for Research on Sarcoma
- Start
- Mar 2017
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in soft tissue sarcoma (STS), osteosarcoma (OS) and chordoma, sponsored by Spanish Group for Research on Sarcoma. Primary endpoint: Progression-Free Survival Rate at 6 months. Started Mar 2017; status: recruiting.
02
Drugs
palbociclib
03
Conditions
soft tissue sarcoma (STS)osteosarcoma (OS)chordoma
Beyond the preview
Go deeper on NCT03242382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03242382.